Jump to navigation
Although the Attorney General of the United States has called the use of medical cannabis as desperate and only slightly less awful than heroin, the miracle plant continues to save lives every day.
One of the most significant positive externalities of the legal cannabis movement has been the decrease in the number of opioid overdose deaths in states with legal medical cannabis programs.
Forbes recently published an article that discussed marijuana’s potential to be an effective stress reducer.
The study also said the results indicate that marijuana compounds may be more effective and safer in alleviating anxiety than prescription anxiety medication (i.e. Xanax, Klonopin, Valium).
Although CNN reported that a study found little evidence that marijuana helps treat chronic pain and PTSD, we beg to differ…
Two studies published in the journal Annals of Internal Medicine found that there was little scientific evidence to support either the effectiveness or safety of medical marijuana.
If Marijuana is Dangerous, Opioids are Nuclear
Although many people associate the legal cannabis industry with the growing and selling of marijuana, the industry has evolved into much more than that.
Canada has proven itself to be a profitable new frontier for cannabis investors and this is just the first inning of a multi-decade growth cycle. While licensed producers have been at the forefront, new opportunities have emerged within the Canadian cannabis market and we want to highlight three undervalued opportunities.
The Canadian cannabis industry continues to offer investors great opportunity as the country plans to legalize recreational cannabis before July 1, 2018, and companies continue to execute ahead of this opportunity.
Although the industry has a major catalyst coming next year, Canadian cannabis stocks have been under significant pressure this year and the stocks have come well off its 2017 highs.
Canabo Medical (CMM.V) (CAMDF: OTCQB) issued a corporate update this morning that highlighted some important company developments following the company’s listing on the TSX Venture Exchange.
Executive Chairman Dr. Neil Smith outlined several key accomplishments that support its focus on being the dominant clinic network, research provider and data analytics source in the cannabis industry.
Although the Canadian medical cannabis industry continues to see incremental growth, a number of issues will need to be resolved.
The biggest challenge is the lack of education and assessment services on the patient and physician level. There are more than 130,000 registered patients and this number has continuesd to see double-digit percentage growth on a month-over-month basis.
Despite the Dow rallying another 220 points and the Nasdaq ending the day above the 6,000, Canadian cannabis stocks were under pressure.
This pressure accelerated throughout the day and followed this tweet from President Trump, “Canada has made business for our dairy farmers in Wisconsin and other border states very difficult. We will not stand for this. Watch!”
The Canadian cannabis industry continues to attract new investors ahead of its plan to legalize recreational cannabis before July 1, 2018.
Recent polls show that most people in the United States support legal cannabis. This is a significant but not surprising development because we have seen economies, both large and small benefit from cannabis legalization or deregulation.
Canabo Continues to Increase Market Share
Since inception, Canabo Medical Inc. (CMM.V: TSX Venture) (CAMDF) has seen significant demand for its services and continues to open new clinics across Canada. Today, the company announced the opening of its 16th clinic in Kelowna, British Columbia, and this facility will be led by Dr. Chemanthi Kalen.
Processing, please wait. This may take up to 15 seconds to complete.
Please do not close your browser.